Evolus, Inc. (NASDAQ:EOLS) Shares Sold by SG Americas Securities LLC

SG Americas Securities LLC lessened its holdings in Evolus, Inc. (NASDAQ:EOLS) by 29.3% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 27,173 shares of the company’s stock after selling 11,274 shares during the period. SG Americas Securities LLC’s holdings in Evolus were worth $300,000 as of its most recent filing with the Securities & Exchange Commission.

Other large investors also recently bought and sold shares of the company. Point72 Asset Management L.P. purchased a new stake in shares of Evolus in the third quarter valued at approximately $132,000. Dynamic Technology Lab Private Ltd acquired a new stake in Evolus in the 3rd quarter valued at $191,000. China Universal Asset Management Co. Ltd. increased its holdings in Evolus by 65.0% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 12,135 shares of the company’s stock worth $197,000 after acquiring an additional 4,780 shares in the last quarter. Algert Global LLC acquired a new position in Evolus during the second quarter worth $210,000. Finally, Oppenheimer & Co. Inc. purchased a new position in Evolus during the third quarter valued at $212,000. Institutional investors and hedge funds own 90.69% of the company’s stock.

Evolus Stock Performance

NASDAQ:EOLS opened at $13.57 on Thursday. The company has a market cap of $859.25 million, a P/E ratio of -14.91 and a beta of 1.33. Evolus, Inc. has a twelve month low of $9.25 and a twelve month high of $17.82. The company’s 50-day moving average price is $11.98 and its 200-day moving average price is $13.91. The company has a current ratio of 2.47, a quick ratio of 2.23 and a debt-to-equity ratio of 20.58.

Analysts Set New Price Targets

EOLS has been the subject of a number of research reports. HC Wainwright reissued a “buy” rating and set a $27.00 target price on shares of Evolus in a research note on Wednesday, January 22nd. Needham & Company LLC reiterated a “buy” rating and set a $22.00 price objective on shares of Evolus in a research note on Tuesday, January 21st. Finally, Barclays increased their target price on Evolus from $20.00 to $22.00 and gave the company an “overweight” rating in a report on Monday, January 27th.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.